PMID- 22954729
OWN - NLM
STAT- MEDLINE
DCOM- 20130509
LR  - 20121019
IS  - 1531-7048 (Electronic)
IS  - 1065-6251 (Linking)
VI  - 19
IP  - 6
DP  - 2012 Nov
TI  - Granulocyte-mobilized bone marrow.
PG  - 448-53
LID - 10.1097/MOH.0b013e32835903ab [doi]
AB  - PURPOSE OF REVIEW: In the last few years, mobilized peripheral blood has overcome 
      bone marrow as a graft source, but, despite the evidence of a more rapid 
      engraftment, the incidence of chronic graft-versus-host disease is significantly 
      higher with, consequently, more transplant-related mortality on the long 
      follow-up. Overall, the posttransplant outcome of mobilized peripheral blood 
      recipients is similar to that of patients who are bone marrow grafted. More 
      recently, the use of bone marrow after granulocyte colony-stimulating factor 
      (G-CSF) donor priming has been introduced in the transplant practice. Herein, we 
      review biological acquisitions and clinical results on the use of G-CSF-primed 
      bone marrow as a source of hematopoietic stem cells (HSC) for allogeneic stem 
      cell transplantation. RECENT FINDINGS: G-CSF the increases the HSC compartment 
      and exerts an intense immunoregulatory effect on marrow T-cells resulting in the 
      shift from Th1 to Th2 phenotype with higher production of anti-inflammatory 
      cytokines. The potential advantages of these biological effects have been 
      translated in the clinical practice by using G-CSF primed unmanipulated bone 
      marrow in the setting of transplant from human leukocyte antigen 
      (HLA)-haploidentical donor with highly encouraging results. SUMMARY: For patients 
      lacking an HLA-identical sibling, the transplant of G-CSF primed unmanipulated 
      bone marrow from a haploidentical donor combined with an intense in-vivo 
      immunosuppression is a valid alternative achieving results that are well 
      comparable with those reported for umbilical cord blood, HLA-matched unrelated 
      peripheral blood/bone marrow or T-cell-depleted haploidentical transplant.
FAU - Arcese, William
AU  - Arcese W
AD  - Rome Transplant Network, Department of Hematology, Stem Cell Transplant Unit, Tor 
      Vergata University, Rome, Italy. william.arcese@uniroma2.it
FAU - De Angelis, Gottardo
AU  - De Angelis G
FAU - Cerretti, Raffaella
AU  - Cerretti R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Hematol
JT  - Current opinion in hematology
JID - 9430802
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Bone Marrow Transplantation/immunology/*methods
MH  - Graft vs Host Disease/immunology/prevention & control
MH  - Granulocyte Colony-Stimulating Factor/*pharmacology
MH  - Granulocytes/*cytology/immunology
MH  - Hematopoietic Stem Cell Mobilization/*methods
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - T-Lymphocytes/immunology
MH  - Transplantation, Homologous
EDAT- 2012/09/08 06:00
MHDA- 2013/05/10 06:00
CRDT- 2012/09/08 06:00
PHST- 2012/09/08 06:00 [entrez]
PHST- 2012/09/08 06:00 [pubmed]
PHST- 2013/05/10 06:00 [medline]
AID - 10.1097/MOH.0b013e32835903ab [doi]
PST - ppublish
SO  - Curr Opin Hematol. 2012 Nov;19(6):448-53. doi: 10.1097/MOH.0b013e32835903ab.